164 related articles for article (PubMed ID: 15801922)
21. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat.
Raso GM; Esposito E; Iacono A; Pacilio M; Cuzzocrea S; Canani RB; Calignano A; Meli R
Eur J Pharmacol; 2009 Feb; 604(1-3):125-31. PubMed ID: 19135440
[TBL] [Abstract][Full Text] [Related]
22. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
Bellot-Rojas P; Posadas-Sanchez R; Caracas-Portilla N; Zamora-Gonzalez J; Cardoso-Saldaña G; Jurado-Santacruz F; Posadas-Romero C
J Drugs Dermatol; 2006 Oct; 5(9):884-9. PubMed ID: 17039655
[TBL] [Abstract][Full Text] [Related]
23. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance.
Burgert TS; Duran EJ; Goldberg-Gell R; Dziura J; Yeckel CW; Katz S; Tamborlane WV; Caprio S
Pediatr Diabetes; 2008 Dec; 9(6):567-76. PubMed ID: 18761646
[TBL] [Abstract][Full Text] [Related]
24. Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Tamura Y; Watada H; Sato F; Kumashiro N; Sakurai Y; Hirose T; Tanaka Y; Kawamori R
Diabetes Obes Metab; 2008 Sep; 10(9):733-8. PubMed ID: 17941868
[TBL] [Abstract][Full Text] [Related]
25. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
Nadeau KJ; Ehlers LB; Zeitler PS; Love-Osborne K
Pediatr Diabetes; 2009 Feb; 10(1):5-13. PubMed ID: 18721166
[TBL] [Abstract][Full Text] [Related]
26. Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial.
Sturm N; Bronowicki JP; Maynard-Muet M; Tran A; Heluwaert F; Plages A; Zarski JP
Gastroenterol Clin Biol; 2009; 33(10-11):984-6. PubMed ID: 19646832
[No Abstract] [Full Text] [Related]
27. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
Zheng LY; Pan JQ; Lv JH
Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
[TBL] [Abstract][Full Text] [Related]
29. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.
Barshop NJ; Sirlin CB; Schwimmer JB; Lavine JE
Aliment Pharmacol Ther; 2008 Jul; 28(1):13-24. PubMed ID: 18397387
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
[TBL] [Abstract][Full Text] [Related]
31. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
32. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
33. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
James AP; Watts GF; Mamo JC
Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
[TBL] [Abstract][Full Text] [Related]
34. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
Rouabhia S; Milic N; Abenavoli L
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):343-9. PubMed ID: 24580044
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF
Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
[TBL] [Abstract][Full Text] [Related]
36. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
37. High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects.
Vilar L; Oliveira CP; Faintuch J; Mello ES; Nogueira MA; Santos TE; Alves VA; Carrilho FJ
Nutrition; 2008; 24(11-12):1097-102. PubMed ID: 18640006
[TBL] [Abstract][Full Text] [Related]
38. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.
Adams LA; Zein CO; Angulo P; Lindor KD
Am J Gastroenterol; 2004 Dec; 99(12):2365-8. PubMed ID: 15571584
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
Loomba R; Lutchman G; Kleiner DE; Ricks M; Feld JJ; Borg BB; Modi A; Nagabhyru P; Sumner AE; Liang TJ; Hoofnagle JH
Aliment Pharmacol Ther; 2009 Jan; 29(2):172-82. PubMed ID: 18945255
[TBL] [Abstract][Full Text] [Related]
40. Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Feb; 98(2):495-9. PubMed ID: 12591075
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
